Growth hormone deficiency in elderly patients with hypothalamo-pituitary tumors

Pituitary. 1998 Apr;1(1):59-67. doi: 10.1023/a:1009923025853.

Abstract

In 18 patients with hypothalamo-pituitary diseases aged over 60 years and in 18 sex, age- and BMI-matched healthy subjects, the results of plasma IGF-I and IGF-BP3 levels and the GH response to GHRH + arginine test (GHRH + ATT) were correlated to the results of body composition, serum osteocalcin (OC) and urinary cross-linked N-telopeptides of type I collagen (Ntx) and the bone mineral density (BMD). In 10 patients and 10 controls, the GH response to ITT was also evaluated. The GH response to GHRH + ATT and ITT was markedly reduced in patients compared to controls (3.1 +/- 0.7 vs. 23.2 +/- 2.3 micrograms/L, P < 0.001 and 1.1 +/- 0.3 vs. 6.4 +/- 0.8 micrograms/L, P < 0.001), so all patients were classified as GHD, though no significant difference was found in plasma IGF-I and IGF-BP3 levels between the two groups. Body composition analysis revealed a significant increase of fat mass (37.4 +/- 2.2 vs. 28.0 +/- 1.0%, P < 0.001), a significant decrease of lean mass (62.6 +/- 2.2 vs. 72.0 +/- 1.0%, P < 0.001) and total body water (45.7 +/- 1.5 vs. 52.5 +/- 1.1%, P < 0.001) in patients compared to controls. Serum OC levels were lower (1.9 +/- 0.1 vs. 4.6 +/- 0.4 micrograms/L, P < 0.001) in patients than in controls, whereas urinary Ntx levels were similar. BMD values in lumbar spine (0.81 +/- 0.02 vs. 0.90 +/- 0.02 g/cm2, P < 0.001) and femoral neck (0.70 +/- 0.02 vs. 0.82 +/- 0.02 g/cm2, P < 0.001) were significantly lower in patients than in controls. A significant inverse correlation was found between GHD duration and lumbar spine (r = -0.73, P&1t; 0.001) or femoral neck (r = -0.81, P&1t; 0.001) BMD values and a significant direct correlation was found between GH peak after GHRH + ATT and lumbar BMD (r = 0.69, p = 0.001) in GHD patients. In conclusion, GHD in patients over 60 yrs aged with a characteristic history of hypothalamus-pituitary pathology is distinct from the physiological decline in GH secretion associated with aging.

MeSH terms

  • Aged
  • Aging / physiology*
  • Arginine
  • Body Composition
  • Bone Density
  • Case-Control Studies
  • Collagen / urine
  • Collagen Type I
  • Female
  • Growth Hormone-Releasing Hormone
  • Human Growth Hormone / deficiency*
  • Human Growth Hormone / metabolism
  • Humans
  • Hypothalamic Neoplasms / diagnosis
  • Hypothalamic Neoplasms / physiopathology*
  • Insulin
  • Insulin-Like Growth Factor Binding Protein 3 / blood
  • Insulin-Like Growth Factor I / metabolism
  • Male
  • Middle Aged
  • Osteocalcin / blood
  • Peptides / urine
  • Pituitary Neoplasms / diagnosis
  • Pituitary Neoplasms / physiopathology*

Substances

  • Collagen Type I
  • Insulin
  • Insulin-Like Growth Factor Binding Protein 3
  • Peptides
  • collagen type I trimeric cross-linked peptide
  • Osteocalcin
  • Human Growth Hormone
  • Insulin-Like Growth Factor I
  • Collagen
  • Growth Hormone-Releasing Hormone
  • Arginine